Bifunctional Inhibition of Human Immunodeficiency Virus Type 1 Reverse Transcriptase: Mechanism and Proof-of-Concept as a Novel Therapeutic Design Strategy
作者:Christopher M. Bailey、Todd J. Sullivan、Pinar Iyidogan、Julian Tirado-Rives、Raymond Chung、Juliana Ruiz-Caro、Ebrahim Mohamed、William Jorgensen、Roger Hunter、Karen S. Anderson
DOI:10.1021/jm400160s
日期:2013.5.23
reverse transcriptase (HIV-1 RT) is a major target for currently approved anti-HIV drugs. These drugs are divided into two classes: nucleoside and non-nucleoside reverse transcriptase inhibitors (NRTIs and NNRTIs). This study illustrates the synthesis and biochemical evaluation of a novel bifunctional RT inhibitor utilizing d4T (NRTI) and a TMC-derivative (a diarylpyrimidine NNRTI) linked via a poly(ethylene
人类免疫缺陷病毒 1 型逆转录酶 (HIV-1 RT) 是目前批准的抗 HIV 药物的主要目标。这些药物分为两类:核苷类和非核苷类逆转录酶抑制剂(NRTIs 和 NNRTIs)。本研究说明了使用 d4T (NRTI) 和通过聚(乙二醇)(PEG)接头连接的 TMC 衍生物(二芳基嘧啶 NNRTI)的新型双功能 RT 抑制剂的合成和生化评估。HIV-1 RT 以碱基特异性方式成功地结合了 d4T-4PEG-TMC 双功能抑制剂的三磷酸盐。此外,该抑制剂表现出低纳摩尔效力,相对于母体 TMC 衍生物和 d4T,体外聚合抑制分别增强了 4.3 倍和 4300 倍。